Semaglutide in Patients with HFpEF and Obesity

Clinical question: Does treatment with semaglutide lead to a reduction in symptoms and physical limitations and improve exercise function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity? Does it affect hospitalizations? Background: Patients with HFpEF and obesity have more adverse clinical features and hemodynamics, more symptoms, worse functional capacity, and more severely impaired quality of life. There is growing evidence that obesity and excess adiposity may play a role in the development and progression of HFpEF. Study design: Randomized, double-blinded, placebo-controlled trial Setting: 13 countries, 96 sites (Asia, Europe, North and South America) Synopsis: 529 patients with HFpEF and obesity with BMI over 30 were randomly assigned to receive a once-weekly dose of 2.4 mg semaglutide (263) or placebo (266) for 1 year. The trial had two primary endpoints looking at changes in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS, range 0 to 100, higher score meaning fewer symptoms) and change in weight. Secondary endpoints included exercise function measured by 6-minute walk distance, HF events, and a composite endpoint which included death. Patients in the semaglutide arm had a change of 16.6 points in KCCQ-CSS from baseline compared to 8.7 in the placebo arm (estimated difference of 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P <0.001). In the semaglutide arm, the mean percentage change in body ...
Source: The Hospitalist - Category: Hospital Management Authors: Tags: In the Literature Source Type: research